High Mobility Group Chromosal Protein N2 Is Expected to be as A Target of Cellular Immunetherapy in Leukemia and Tumors.
10.7534/j.issn.1009-2137.2015.04.001
- Author:
Huan-Huan LI
1
;
Ping ZHU
2
;
Xue-Qiang WU
1
;
Yu-Feng LIU
3
;
Li-Hua WANG
1
Author Information
1. Institute of Hematology & Oncology, Beijing Aerospace General Hospital, Beijing 100076, China.
2. Department of Hematology, Peking University Fist Hospital, Beijing 100034, China. E-mail: zhupingbj@gmail.com.
3. Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
- Publication Type:Journal Article
- MeSH:
Antigens, CD19;
Antigens, Neoplasm;
CD8-Positive T-Lymphocytes;
HMGN2 Protein;
Humans;
Immunotherapy;
Leukemia;
Neoplasms;
Receptors, Antigen, T-Cell
- From:
Journal of Experimental Hematology
2015;23(4):915-918
- CountryChina
- Language:Chinese
-
Abstract:
Recently, chimeric antigen receptors T cells (CAR T) have made a breakthrough in the treatment of lymphoma and leukemia, open a new path for the tumor cellular immunetherapy. It is the key for CAR T to take the gene which can identify the CD19 antigen of lymphoblastic leukemia into lymphocytes, enable it to kill leukemia cells with specific cell-surface loci. The same principle also applies to other aspects, if we find specific target genes of lymphocytes. Recent studies have found that high mobility group protein N2 (high mobility group chromosal protein N2, HMGN2) is the excellent target of tumor-associated antigen in lymphocytes, is the antitumor effector molecule of CD8(+) T cells, which has the ability of trends and specific identify/binding in myeloid leukemia, breast cancer, cervical cancer and other tumor cells. HMGN2 is expected to be used for the preparation of specific identification of tumor lymphocytes and to treat more leukemia and tumors. This article focuses on the strucure and function of HMGN and the chemotaxis and antitumor effect of HMGN2 in leukemia and tumors.
